TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time between gel administration and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Area Under the Curve From Time 0 to t, AUC (0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute suction work using MAPSE and IVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in lean tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elimination Rate Constants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants surviving to 12 months of age
Endpoint domain: Mortality/survival
Primary endpoint: Attendance at Cardiac Rehabilitation Exercise Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidences of Second primary malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area of Tissue Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Fragments < 2 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Output Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of cefepime and AAI101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf: area under the concentration-time curve (AUC) from time 0 extrapolated to infinity of cefepime and AAI101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of residual neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of TEAEs (treatment-emergent adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with DLTs (dose-limiting toxicities)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with 1 or more SAEs (serious adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Motor Learning test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of neurological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of liver cirrhosis, decompensation or liver cancer
Endpoint domain: Mortality/survival
Primary endpoint: Clearance of Central Venous Line Infection by Day 6
Endpoint domain: Adverse events/effects
Primary endpoint: Inclination angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Efficacy for Daily Activities (SEDA) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of opportunist diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in CD4+ cell count and CD4+/CD8+ ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Polyfunctionality of T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with babies having macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Seconds of active phone use per hour of driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate (complete and partial remissions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of operated hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intraoperative Propofol Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death (all cause)
Endpoint domain: Mortality/survival
Primary endpoint: any ischemic event leading to rehospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: any evidence of organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss since baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SCL depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in IVUS-assessed Plaque Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of heterophilic antibodies in the serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Altered PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Best Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: food intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac index during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to composite of total mortality and hospitalization for heart failure and atherothrombotic disease
Endpoint domain: Mortality/survival
Primary endpoint: Change in Kinematic Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Foot Placement Targeting Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of professional situations
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of children who repeated a grade
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in ASD Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic pulmonary pressure at 50 W
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Neutralizing Antibody Titers Against RSV-A Subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PET-CT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in incretin-mediated insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Receptor regulation of glucose-dependent insulinotropic peptide (GIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With Psoriatic Arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remodeling (LV ESV reduction or LV EF increase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological changes in pupil diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological changes in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physiological changes in heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Time Spent With Arterial Oxygen Saturation < 75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lowering of post-prandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of difficult pre-hospital endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Subjects with HbA1c ≥ 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vitamin B12 cumulative supplement quantity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Technical Success of Balloon Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of no reflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First Pass Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to block regression to the S1 dermatome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Control of delayed nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Comfort Level of Stenfilcon A and Narafilcon A Lenses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dryness of Stenfilcon A and Narafilcon A Lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD) and dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: immunogenicity of a multi-epitope peptide vaccine
Endpoint domain: Physiological/clinical
Primary endpoint: Mean Changes in Count of Generalized Spike-wave Discharges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Days With Any Generalized Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With One or More Solicited Systemic Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With One or More Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of First Diagnosis of Active Tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: Death Related to Tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: Death From Unknown Cause
Endpoint domain: Mortality/survival
Primary endpoint: Changes of pharyngeal motor evoked potential amplitudes (PMEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of Seroquel in anorexia nervosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breathlessness, Cough, and Sputum Scale (BCSS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with at least one Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: rate of wound drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum serum insulin degludec concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum serum insulin aspart concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-operative recovery of respiratory function (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative recovery of health-related quality of life (EQ5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in size of brain region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Complete Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Radiographic Measurement of Alveolar Ridge Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Early Onset Primary Adverse Events (PAEs): Atrio-esophageal Fistula and Pulmonary Vein (PV) Stenosis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Early Onset PAEs: Death, Myocardial Infraction, Cardiac Tamponade/Perforation, Thromboembolism, Stroke/Cardiovascular Accident, TIA, PNP, Heart Block, Pulmonary Edema, Vagal Nerve Injury, Pericarditis, and MVAC/Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Freedom From Documented Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes or Other Failure Modes
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ventricular fibrillation or sudden death
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Subjects With Severe Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Subjects With Diabetic Ketoacidosis (DKA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time in Range 70-180 mg/dL During Target Blood Glucose Challenge Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Benefit Rate (CR, PR, SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in RV/LV Ratio on Echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All-cause Mortality During First 12 Months Post-procedure
Endpoint domain: Mortality/survival
Primary endpoint: Change in Quality of Life (QOL) as Measured by the Pulmonary Embolism Quality of Life (PEmb-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Days of Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of change in renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pediatric cGVHD symptom scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Haemotological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Micronutrient status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of infectious diseases total morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Primigravidas who request a Non-Indicated CS
Endpoint domain: Adverse events/effects
Primary endpoint: Balance as measured by mCTSIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmatic Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasmatic Insulin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Food literacy level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freedom from adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacodynamic effect measured by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of COVID-19 progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Interdental plaque score - after first use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interdental plaque score - after 4 weeks of usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival index - after 4 weeks of usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product failure
Endpoint domain: Adverse events/effects
Primary endpoint: Obtains first prescription for PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in satiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response at week 6-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Status Score for the Intensive Care Unit (FSS-ICU)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in 6-Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac and cerebrovascular events (MACCEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Cannabinoid Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammation: Circulating Levels of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Energy Levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Myalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fever/Chills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in laboratory markers of cardiovascular and diabetes risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Carotid Plaque Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline of the Insulin Secretion Rate (ISR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline to End of Study in LOCF VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number and percentage of subjects with treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: local and/or systematic recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lens Opacity Classification System (LOCS) III grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic status: Major Depressive Episode Using The SCID-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms (clinician-rated) Hamilton Rating Scale for Depression (HRS-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress and social functioning (Global Axis of Functioning using the SCID-IV)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Immune-related Objective Response Rate (iORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-cell subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concordance of HPV positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of wounds that close
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of Nexium in combination with oral taxane
Endpoint domain: Adverse events/effects
Primary endpoint: Exposure levels of oral taxane in the body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative incidence of death
Endpoint domain: Mortality/survival
Primary endpoint: cumulative incidence of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative incidence of major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: WOMAC pain score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under serum concentration-time curve from zero to infinity [AUC]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum concentration [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum observed serum concentration [tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: real-time quantitative PCR levels of EBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in heroin use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Density value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Target VASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pulp test using thermal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pulp test using electrical test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Protein Synthesis (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of patient anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in level of patient motion sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to neuro-cognitive progression as assessed by the Mini Mental State Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Head thrust test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruininks-Oseretsky test of motor proficiency (BOT-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes